172 related articles for article (PubMed ID: 22305627)
1. Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer.
Peppercorn J; Armstrong A; Zaas DW; George D
Urol Oncol; 2013 Oct; 31(7):1079-84. PubMed ID: 22305627
[TBL] [Abstract][Full Text] [Related]
2. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
[TBL] [Abstract][Full Text] [Related]
3. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
Wei XX; Fong L; Small EJ
Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.
Davis K; Wood S; Dill E; Fesko Y; Bitting RL; Harrison MR; Armstrong AJ; Moul JW; George DJ
Clin J Oncol Nurs; 2015 Jun; 19(3):297-303. PubMed ID: 26000580
[TBL] [Abstract][Full Text] [Related]
5. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
Mulders PF; De Santis M; Powles T; Fizazi K
Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563
[TBL] [Abstract][Full Text] [Related]
6. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
Di Lorenzo G; Ferro M; Buonerba C
BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
[TBL] [Abstract][Full Text] [Related]
7. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.
Handy CE; Antonarakis ES
Future Oncol; 2018 Apr; 14(10):907-917. PubMed ID: 29260582
[TBL] [Abstract][Full Text] [Related]
8. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
Sims RB
Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer.
Holko P; Kawalec P
Expert Rev Anticancer Ther; 2014 Jan; 14(1):63-73. PubMed ID: 24224852
[TBL] [Abstract][Full Text] [Related]
10. Current role of immunotherapy for the treatment of prostate cancer.
Porfyris O; Kalomoiris P
J BUON; 2013; 18(4):809-17. PubMed ID: 24344002
[TBL] [Abstract][Full Text] [Related]
11. Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention.
Jarosławski S; Toumi M
BioDrugs; 2015 Oct; 29(5):301-7. PubMed ID: 26403092
[TBL] [Abstract][Full Text] [Related]
12. Regulation of biologic oncology products in the FDA׳s Center for Biologics Evaluation and Research.
Bross PF; Fan C; George B; Shannon K; Joshi BH; Puri RK
Urol Oncol; 2015 Mar; 33(3):133-6. PubMed ID: 25441459
[TBL] [Abstract][Full Text] [Related]
13. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.
Quinn DI; Vaishampayan U; Higano CS; Lin DW; Shore ND; Beer TM
Expert Rev Anticancer Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24224900
[TBL] [Abstract][Full Text] [Related]
14. Role of immunotherapy in castration-resistant prostate cancer (CRPC).
Suárez C; Morales-Barrera R; Ramos V; Núñez I; Valverde C; Planas J; Morote J; Maldonado X; Carles J
BJU Int; 2014 Mar; 113(3):367-75. PubMed ID: 23650874
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatment].
Djurhuus SS; Brasso K; Berg KD; Iversen P; Røder MA
Ugeskr Laeger; 2015 May; 177(20):. PubMed ID: 25967247
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for advanced prostate cancer: a novel treatment option to improve survival.
Peskin SR
Manag Care; 2011 Sep; 20(9 Suppl 5):3-4, 6-11. PubMed ID: 22046617
[TBL] [Abstract][Full Text] [Related]
17. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.
Cheever MA; Higano CS
Clin Cancer Res; 2011 Jun; 17(11):3520-6. PubMed ID: 21471425
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutics for the treatment of prostate cancer: a patent landscape based on key therapeutic mechanisms of actions.
Harris E
Pharm Pat Anal; 2018 Jan; 7(1):47-57. PubMed ID: 29227196
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
Garcia JA; Dreicer R
Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
[TBL] [Abstract][Full Text] [Related]
20. The evolving landscape of immunotherapy in advanced prostate cancer.
Patel VG; Oh WK
Immunotherapy; 2019 Jul; 11(10):903-912. PubMed ID: 31161846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
